Annals of medicine · 2026
Population pharmacokinetic-based dose adjustment of tiapride in patients with impaired renal function.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Halouzková Barbora Agatha, Jelínková Michaela, Hartinger Jan Miroslav, Šíma Martin, Hrušková Zdenka, Hladinová Zuzana, Grus Tomáš, Špaček Miroslav, Škrha Jan, Toušek Petr, Tesař Vladimír, Slanař Ondřej
Аннотация
BACKGROUND: Tiapride is widely used for the treatment of confusion in the elderly and for other indications. Kidney impairment is common in the elderly population and may influence tiapride pharmacokinetics. However, pharmacokinetic alterations of tiapride in patients with kidney disease have not been described so far.
METHODS: We studied tiapride pharmacokinetics in 71 predominantly elderly patients with various degrees of kidney impairment, including patients receiving hemodialysis. A population pharmacokinetic model and Monte Carlo simulations were used to evaluate tiapride exposure and optimize dosing across different degrees of renal impairment.
RESULTS: Tiapride pharmacokinetics was strongly dependent on renal function, while other tested covariates had no significant effect. Drug exposure was approximately fivefold higher in patients with severe kidney impairment, indicating the need for substantial dose reduction to prevent overdose. The model enabled development of dosing recommendations for patients with CKD, including those receiving hemodialysis. Due to prolonged elimination in advanced CKD, drug effects may persist for several days after discontinuation.
CONCLUSION: Renal function is the key determinant of tiapride pharmacokinetics. These findings provide practical dosing recommendations for elderly patients with kidney impairment and may improve the safety of tiapride therapy in clinical practice.
METHODS: We studied tiapride pharmacokinetics in 71 predominantly elderly patients with various degrees of kidney impairment, including patients receiving hemodialysis. A population pharmacokinetic model and Monte Carlo simulations were used to evaluate tiapride exposure and optimize dosing across different degrees of renal impairment.
RESULTS: Tiapride pharmacokinetics was strongly dependent on renal function, while other tested covariates had no significant effect. Drug exposure was approximately fivefold higher in patients with severe kidney impairment, indicating the need for substantial dose reduction to prevent overdose. The model enabled development of dosing recommendations for patients with CKD, including those receiving hemodialysis. Due to prolonged elimination in advanced CKD, drug effects may persist for several days after discontinuation.
CONCLUSION: Renal function is the key determinant of tiapride pharmacokinetics. These findings provide practical dosing recommendations for elderly patients with kidney impairment and may improve the safety of tiapride therapy in clinical practice.